Florian van Bömmel
A5072894234- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis Viruses Studies and Epidemiology
- HIV/AIDS drug development and treatment
- Liver Disease and Transplantation
- HIV Research and Treatment
- Blood groups and transfusion
- Cancer Immunotherapy and Biomarkers
- Immune Response and Inflammation
- Cytomegalovirus and herpesvirus research
- Liver Diseases and Immunity
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Treatments and Mutations
- Drug-Induced Hepatotoxicity and Protection
- Vibrio bacteria research studies
- Immunotherapy and Immune Responses
- Influenza Virus Research Studies
- Systemic Lupus Erythematosus Research
- Viral Infections and Outbreaks Research
- Animal Virus Infections Studies
- Cancer, Lipids, and Metabolism
- Immunodeficiency and Autoimmune Disorders
- Colorectal Cancer Treatments and Studies
Leipzig University
2013-2025
University Hospital Leipzig
2016-2025
University Medical Center
2020-2025
Klinik und Poliklinik für Neurologie
2011-2024
Karolinska Institutet
2022
GTx (United States)
2019
Research Triangle Park Foundation
2018
University of North Carolina at Chapel Hill
2018
Center for Rheumatology
2017
Charité - Universitätsmedizin Berlin
2004-2015
Adefovir dipivoxil was recently approved for the treatment of wild–type and lamivudine–resistant hepatitis B virus (HBV) infection. Tenofovir disoproxil fumarate, a congender adefovir that is used in HIV infected patients, has been shown to also be effective patients with HBV We therefore compared two substances study 53 defined by high DNA (>6 log10 copies/mL) levels genotypic evidence lamivudine resistance. Thirty–five received tenofovir 72 130 weeks, 18 60 80 weeks. Changes were...
Tenofovir disoproxil fumarate (TDF) has demonstrated high antiviral efficacy in treatment-naive patients with chronic hepatitis B virus (HBV) infection but experience nucleoside/nucleotide analogue (NA)-experienced is limited. In this retrospective multicenter study we therefore assessed the long-term of TDF monotherapy prior failure or resistance to different NA treatments. Criteria for inclusion were HBV DNA levels >4.0 log10 copies/mL at start and a minimum period therapy least 6...
Whether there is a change of hepatocellular carcinoma (HCC) incidence in chronic hepatitis B patients under long‐term therapy with potent nucleos(t)ide analogues currently unclear. We therefore assessed the HCC beyond year 5 entecavir/tenofovir (ETV/TDF) and tried to determine possible factors associated late occurrence. This European, 10‐center, cohort study included 1,951 adult Caucasian without at baseline who received ETV/TDF for ≥1 year. Of them, 1,205 (62%) within first years have been...
Hepatitis B envelope antigen (HBeAg) seroconversion represents an endpoint of treatment chronic hepatitis virus (HBV) infections. We have studied whether levels serum HBV RNA during polymerase inhibitor might be helpful for predicting HBeAg seroconversion. were determined in serial samples from 62 patients with infection (50 positive). Patients received antiviral a mean duration 30 ± 15 (range, 4-64) months. A new rapid amplification complimentary DNA-ends-based real-time chain reaction was...
Current blood biomarkers are suboptimal in detecting drug‐induced liver injury (DILI) and predicting its outcome. We sought to characterize the natural variabilty performance characteristics of 14 promising DILI biomarker candidates. Serum or plasma from multiple cohorts healthy volunteers (n = 192 n 81), subjects who safely took potentially hepatotoxic drugs without adverse effects 55 92) patients 98, 28, 143) were assayed for microRNA‐122 (miR‐122), glutamate dehydrogenase (GLDH), total...
Hepatocellular carcinoma (HCC) risk-scores may predict HCC in Asian entecavir (ETV)-treated patients. We aimed to study risk factors and performance of scores during ETV treatment an ethnically diverse Western population.We studied all HBV monoinfected patients treated with from 11 European referral centres within the VIRGIL Network.A total 744 were included; 42% Caucasian, 29% Asian, 19% other, 10% unknown. At baseline, 164 (22%) had cirrhosis. During a median follow-up 167 (IQR 82-212)...
Nucleo(s)tide analogue (NUC) withdrawal may result in HBsAg clearance a subset of patients. However, predictors loss after NUC remain ill-defined.We studied global cohort HBeAg-negative patients with undetectable HBV DNA who discontinued long-term therapy. Patients requiring retreatment treatment cessation were considered non-responders.We enrolled 1,216 (991 genotype data); 98 (8.1%) achieved loss. The probability was higher non-Asian (adjusted hazard ratio [aHR] 8.26, p <0.001), and lower...
Incomplete virological response to adefovir dipivoxil (ADV) has been observed in patients with lamivudine-resistant hepatitis B virus (HBV) infection and may be associated developing resistance disease progression. We therefore investigated whether the efficacy of viral suppression could improved by replacing ADV tenofovir disoproxil fumarate (TDF). Twenty chronic HBV (18 HBeAg+), breakthrough during lamivudine therapy, persistent replication (>104 copies/mL) after 15 months monotherapy...
Entecavir (ETV) is a potent inhibitor of viral replication in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B (CHB) patients. The aim this study was to investigate the long term efficacy and safety ETV NA-naïve CHB patients, particularly those with detectable virus (HBV) DNA after 48 weeks, whom treatment adaptation suggested by current guidelines. In multicenter cohort study, we investigated 333 patients treated entecavir monotherapy. population consisted 243 whereas 90 were...
Ancient DNA traces the history of hepatitis B Hepatitis virus (HBV) infections represent a worldwide human health concern. To study this pathogen, Kocher et al . identified 137 remains with detectable levels dating between 400 and 10,000 years ago. Sequencing analyses these ancient viruses suggested common ancestor 12,000 20,000 There is no evidence indicating that HBV was present in earliest humans as they spread out Africa; however, likely populations before farming. Furthermore, Americas...
Predictors of successful nucleo(s)tide analogue (NA) therapy withdrawal remain elusive. We studied the relationship between end-of-treatment levels hepatitis B core-related antigen (HBcrAg) and surface (HBsAg) outcome after cessation.Patients who discontinued NA in centers Asia Europe were enrolled. HBcrAg HBsAg measured at treatment cessation, associations with off-treatment outcomes explored. The SCALE-B (Surface antigen, Core-related Age, ALT, tenofovir for HBV) score was calculated as...
Abstract Background People with chronic hepatitis B (CHB) commonly experience social and self-stigma. This study sought to understand the impacts of CHB-related stigma a functional cure on stigma. Methods Adults CHB wide range age education were recruited from 5 countries participated in 90-minute qualitative, semi-structured interviews explore concepts related CHB-associated its impact. Participants answered open-ended concept-elicitation questions regarding their self-stigma, potential...